Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quinnova Pharmaceuticals, a specialty pharmaceutical company, has launched Neosalus, the first non-steroidal anti-inflammatory prescription topical foam product for the treatment of various types of dermatoses including atopic dermatitis and hand eczema.
Subscribe to our email newsletter
Neosalus, formulated with Quinnova’s patented Proderm Technology, provides skin barrier repair, protection, and moisturization.
Christopher Hensby, senior vice president of Quinnova, said: “To treat recalcitrant skin conditions such as atopic dermatitis and hand eczema, a comprehensive and long term solution is required to address the underlying issue of a compromised skin barrier while reducing inflammation.
“First and foremost, Neosalus helps to restore a dysfunctional skin barrier by replenishing the lost lipids, thereby decreasing trans-epidermal water loss. Furthermore, Neosalus functions as a protectant to reduce the penetration of irritants from further exacerbating the itch and scratch cycle. Finally, Neosalus has anti-inflammatory ability that helps to reduce the frequency and severity of flare-ups, thus making it a steroid sparing and complementary treatment to other concomitant treatments.”